StreetInsider.com News Articles

Thiogenesis Announces FDA Clearance of IND for Nephropathic Cystinosis

Thu, 22 Oct 2026 05:00:00 -0400

Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence

San Diego, California--(Newsfile Corp. - October 22, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug ("IND") application for TTI-0102 in nephropathic cystinosis. On October 16, 2026, the FDA issued a "Study May Proceed" letter for IND 184780. The IND is now in effect and supports the investigator-initiated study announced on February 2, 2026.

The study, TTI-CYST-001, will be conducted at Emory

Thiogenesis Announces FDA Clearance of IND for Nephropathic Cystinosis

Thu, 22 Oct 2026 05:00:00 -0400

Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence

The study, TTI-CYST-001, will be conducted at Emory

Thiogenesis Announces FDA Clearance of IND for Nephropathic Cystinosis

Thu, 22 Oct 2026 05:00:00 -0400

Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence

The study, TTI-CYST-001, will be conducted at Emory

Thiogenesis Announces FDA Clearance of IND for Nephropathic Cystinosis

Thu, 22 Oct 2026 05:00:00 -0400

Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence

The study, TTI-CYST-001, will be conducted at Emory

Thiogenesis Announces FDA Clearance of IND for Nephropathic Cystinosis

Thu, 22 Oct 2026 05:00:00 -0400

Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence

The study, TTI-CYST-001, will be conducted at Emory

Thiogenesis Announces FDA Clearance of IND for Nephropathic Cystinosis

Thu, 22 Oct 2026 05:00:00 -0400

Investigator-initiated study led by Dr. Larry Greenbaum of Emory University to evaluate once-daily oral powder TTI-0102, designed to improve adherence

The study, TTI-CYST-001, will be conducted at Emory

Form 8-K TETRA TECHNOLOGIES INC For: Oct 02

Thu, 08 Oct 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20261008/27163476.html

Form SCHEDULE 13G/A TETRA TECHNOLOGIES INC Filed by: Neuberger Berman Group LLC

Tue, 06 Oct 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20261006/27155784.html

Clear Street Upgrades TETRA Technologies Inc. (TTI) to Buy

Tue, 06 Oct 2026 06:13:05 -0400

(Updated - October 6, 2026 6:13 AM EDT)

Clear Street analyst Tim Moore upgraded TETRA Technologies Inc. (NYSE: TTI) from Hold to Buy with a price target of $11.00.

The analyst comments "We upgrade TETRA Technologies (TTI) to a Buy from Hold to reflect the upside potential to our $11 price target, as we move our price target basis to 2028 from 2027. In January, we downgraded the stock to Hold when the stock price appeared frothy at $11-12, and we were unconvinced TTI would have desalination revenue in 2027 from datacenters. We now value the stock on 2028 EBITDA, which includes

Clear Street Upgrades TETRA Technologies Inc. (TTI) to Buy

Tue, 06 Oct 2026 06:13:05 -0400

(Updated - October 6, 2026 6:13 AM EDT)

Clear Street analyst Tim Moore upgraded TETRA Technologies Inc. (NYSE: TTI) from Hold to Buy with a price target of $11.00.

Form 4 TETRA TECHNOLOGIES INC For: Oct 04 Filed by: Moeller Timothy C

Mon, 05 Oct 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20261005/27149128.html

Form 4 TETRA TECHNOLOGIES INC For: Sep 29 Filed by: Kokenes Kathrine

Wed, 30 Sep 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260930/27128958.html

TETRA TECHNOLOGIES, INC. ANNOUNCES DATE FOR THIRD QUARTER 2026 EARNINGS CONFERENCE CALL

Wed, 30 Sep 2026 13:14:00 -0400

SPRING, Texas, Sept. 30, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE: TTI) will release Third Quarter 2026 results after the market closes on November 2, 2026 and will host a conference call to discuss the results and outlook on November 3, 2026, at 10:00am ET. CLICK HERE to pre-register and obtain your dial in number and passcode. A replay will be available for thirty days following the conference call.

TETRA TECHNOLOGIES, INC. ANNOUNCES DATE FOR THIRD QUARTER 2026 EARNINGS CONFERENCE CALL

Wed, 30 Sep 2026 13:14:00 -0400

TETRA Technologies Inc. (TTI) PT Lowered to $12 at Stifel Amid Lack of Desalination Contracts

Wed, 23 Sep 2026 07:03:14 -0400

Stifel analyst Stephen Gengaro lowered the price target on TETRA Technologies Inc. (NYSE: TTI) to $12.00 (from $13.00) while maintaining a Buy rating.

The analyst commented, "TETRA shares have slid 46.9% since June 30 versus a 3.5% rise in the S&P 500 and a 16.6% rise in the XLE. We attribute the weakness to a few factors, including the lack of visible progress (i.e., a contract) in the water desalination business, uncertainty on the ramp in Eos Energy (EOSE: $4.06, Buy) production, and possibly some well timing in the Fluids that impacts 2H26 results. We maintain our Buy and are trimming

TETRA Technologies Inc. (TTI) PT Lowered to $12 at Stifel Amid Lack of Desalination Contracts

Wed, 23 Sep 2026 07:03:14 -0400

Stifel analyst Stephen Gengaro lowered the price target on TETRA Technologies Inc. (NYSE: TTI) to $12.00 (from $13.00) while maintaining a Buy rating.

Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update

Mon, 21 Sep 2026 04:00:00 -0400

San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones.

Meeting Results

All items of business put before shareholders at the Meeting were approved by the requisite majority of votes cast.

Shareholders elected the following directors to serve until the next annual meeting or until their successors are elected or appointed: Dr.

Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update

Mon, 21 Sep 2026 04:00:00 -0400

San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones.
Meeting Results
All items of business put before shareholders at the Meeting were approved by the requisite majority of votes cast.
Shareholders elected the following directors to serve until the next annual meeting or until their successors are elected or appointed: Dr.

Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update

Mon, 21 Sep 2026 04:00:00 -0400

San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones.
Meeting Results
All items of business put before shareholders at the Meeting were approved by the requisite majority of votes cast.
Shareholders elected the following directors to serve until the next annual meeting or until their successors are elected or appointed: Dr.

Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update

Mon, 21 Sep 2026 04:00:00 -0400

San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones.
Meeting Results
All items of business put before shareholders at the Meeting were approved by the requisite majority of votes cast.
Shareholders elected the following directors to serve until the next annual meeting or until their successors are elected or appointed: Dr.

Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update

Mon, 21 Sep 2026 04:00:00 -0400

San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones.
Meeting Results
All items of business put before shareholders at the Meeting were approved by the requisite majority of votes cast.
Shareholders elected the following directors to serve until the next annual meeting or until their successors are elected or appointed: Dr.

Thiogenesis Reports Results of 2026 Annual and Special Meeting of Shareholders and Provides Corporate Update

Mon, 21 Sep 2026 04:00:00 -0400

San Diego, California--(Newsfile Corp. - September 21, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biopharmaceutical company developing sulfur-based therapeutics for serious pediatric diseases, today announced the results of its Annual and Special Meeting of Shareholders ("Meeting") held on September 8, 2026, and provided a corporate update highlighting recent clinical, regulatory, and financial milestones.
Meeting Results
All items of business put before shareholders at the Meeting were approved by the requisite majority of votes cast.
Shareholders elected the following directors to serve until the next annual meeting or until their successors are elected or appointed: Dr.

Thiogenesis Engages Brisco Capital for Investor Relations

Thu, 03 Sep 2026 06:00:00 -0400

San Diego, California--(Newsfile Corp. - September 3, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing sulfur-based therapeutics for rare diseases, today announced that it has engaged Brisco Capital Partners Corp. ("Brisco") to provide investor relations services.
Brisco will assist the Company in expanding communications with shareholders, investors and the broader investment community to increase awareness of Thiogenesis and its development programs.
Brisco is a Calgary, Alberta based investor relations firm providing services to a number of public companies including business development, road shows, corporate communications and tradeshow advisory. Brisco currently owns

Thiogenesis Engages Brisco Capital for Investor Relations

Thu, 03 Sep 2026 06:00:00 -0400

San Diego, California--(Newsfile Corp. - September 3, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing sulfur-based therapeutics for rare diseases, today announced that it has engaged Brisco Capital Partners Corp. ("Brisco") to provide investor relations services.
Brisco will assist the Company in expanding communications with shareholders, investors and the broader investment community to increase awareness of Thiogenesis and its development programs.
Brisco is a Calgary, Alberta based investor relations firm providing services to a number of public companies including business development, road shows, corporate communications and tradeshow advisory. Brisco currently owns

Thiogenesis Engages Brisco Capital for Investor Relations

Thu, 03 Sep 2026 06:00:00 -0400

San Diego, California--(Newsfile Corp. - September 3, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQB: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing sulfur-based therapeutics for rare diseases, today announced that it has engaged Brisco Capital Partners Corp. ("Brisco") to provide investor relations services.
Brisco will assist the Company in expanding communications with shareholders, investors and the broader investment community to increase awareness of Thiogenesis and its development programs.
Brisco is a Calgary, Alberta based investor relations firm providing services to a number of public companies including business development, road shows, corporate communications and tradeshow advisory. Brisco currently owns